Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases
Location: United Kingdom
Employees: 11-50
Total raised: $5.09M
Founded date: 2023
Investors 1
| Date | Name | Website |
| - | Epidarex C... | epidarex.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.11.2023 | - | $5.09M | - |
Mentions in press and media 5
| Date | Title | Description |
| 30.05.2024 | Harness Therapeutics appoints Leading World Experts in Neurodegenerative Diseases to its Scientific Advisory Board (SAB) | Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001 Cambridge, UK, May 30, 2024: Harness Therapeutics, a biotechnology company... |
| 30.11.2023 | Harness Therapeutics Raises Additional £4M in Funding | Harness Therapeutics, a Cambridge, UK-based biotechnology company focused on physiological protein upregulation, raised additional £4M in funding. The round brought the total amount to £17.6M. Backers included SV Health Investors, investing... |
| 28.11.2023 | Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases | Cambridge, UK, 28th November 2023: Harness Therapeutics (‘Harness’, previously Transine Therapeutics), a biotechnology company focused on physiological protein upregulation to develop next generation therapeutics for the treatment of neurod... |
| 28.11.2023 | Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases | - |
| - | Harness Therapeutics | “Harness Therapeutics” |